Baxter/Halozyme's HyQvia wins EU nod for immunodeficiencies

05/23/2013 | PharmaTimes (U.K.)

Baxter International and Halozyme Therapeutics obtained approval from the European Commission to market HyQvia as a replacement treatment for adults with primary and secondary immunodeficiency disorders. The treatment, a combination of human normal immunoglobulin and recombinant human hyaluronidase, is intended to be taken once every three to four weeks.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR